 Xiayuan Liang
Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2020 | 269 | 1.280 |
Why?
| | Receptor Protein-Tyrosine Kinases | 7 | 2013 | 225 | 0.740 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 4 | 2016 | 97 | 0.720 |
Why?
| | Leukemia, B-Cell | 1 | 2020 | 11 | 0.720 |
Why?
| | Gene Rearrangement | 3 | 2013 | 135 | 0.690 |
Why?
| | Biomarkers, Tumor | 4 | 2018 | 1048 | 0.680 |
Why?
| | Lymphoma, B-Cell | 1 | 2020 | 86 | 0.660 |
Why?
| | Lymphoma, Extranodal NK-T-Cell | 1 | 2018 | 8 | 0.640 |
Why?
| | Lymphoma, T-Cell, Peripheral | 1 | 2018 | 15 | 0.630 |
Why?
| | Genetic Association Studies | 1 | 2018 | 343 | 0.550 |
Why?
| | Lymphoma, Large-Cell, Anaplastic | 1 | 2013 | 15 | 0.440 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2013 | 114 | 0.410 |
Why?
| | Lymphoproliferative Disorders | 2 | 2008 | 46 | 0.350 |
Why?
| | Genetic Predisposition to Disease | 1 | 2018 | 2125 | 0.350 |
Why?
| | Killer Cells, Natural | 2 | 2008 | 383 | 0.290 |
Why?
| | Flow Cytometry | 5 | 2018 | 1083 | 0.280 |
Why?
| | In Situ Hybridization, Fluorescence | 4 | 2013 | 310 | 0.270 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2007 | 71 | 0.260 |
Why?
| | Chromosome Aberrations | 3 | 2018 | 134 | 0.260 |
Why?
| | Leukemia | 1 | 2008 | 209 | 0.260 |
Why?
| | Hodgkin Disease | 1 | 2007 | 118 | 0.250 |
Why?
| | DNA Nucleotidylexotransferase | 1 | 2004 | 11 | 0.240 |
Why?
| | Proto-Oncogene Proteins | 4 | 2010 | 609 | 0.240 |
Why?
| | Child | 14 | 2020 | 18488 | 0.240 |
Why?
| | Proto-Oncogenes | 1 | 2004 | 26 | 0.240 |
Why?
| | Cytogenetic Analysis | 2 | 2020 | 29 | 0.240 |
Why?
| | Eye Neoplasms | 1 | 2003 | 15 | 0.230 |
Why?
| | Lymphoma, B-Cell, Marginal Zone | 1 | 2003 | 11 | 0.230 |
Why?
| | Stem Cells | 1 | 2008 | 546 | 0.230 |
Why?
| | Protein-Tyrosine Kinases | 2 | 2004 | 396 | 0.220 |
Why?
| | Immunohistochemistry | 4 | 2013 | 1642 | 0.210 |
Why?
| | Anaplasia | 1 | 2002 | 2 | 0.200 |
Why?
| | Child, Preschool | 9 | 2019 | 9133 | 0.200 |
Why?
| | Hyaluronan Receptors | 1 | 2002 | 91 | 0.200 |
Why?
| | Infant | 9 | 2019 | 7979 | 0.180 |
Why?
| | Glycoproteins | 1 | 2002 | 309 | 0.180 |
Why?
| | Retrospective Studies | 6 | 2020 | 12608 | 0.170 |
Why?
| | Liver Transplantation | 1 | 2007 | 830 | 0.170 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1361 | 0.170 |
Why?
| | Translocation, Genetic | 2 | 2013 | 93 | 0.160 |
Why?
| | Castleman Disease | 1 | 2019 | 13 | 0.160 |
Why?
| | Lymphohistiocytosis, Hemophagocytic | 1 | 2019 | 28 | 0.160 |
Why?
| | Karyotyping | 1 | 2018 | 102 | 0.160 |
Why?
| | Histocytochemistry | 1 | 2018 | 78 | 0.160 |
Why?
| | Immunophenotyping | 3 | 2004 | 277 | 0.160 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 138 | 0.150 |
Why?
| | Male | 12 | 2019 | 55949 | 0.140 |
Why?
| | Prognosis | 4 | 2019 | 3339 | 0.140 |
Why?
| | Humans | 21 | 2020 | 115587 | 0.140 |
Why?
| | Organic Cation Transport Proteins | 1 | 2016 | 26 | 0.140 |
Why?
| | Transcription Factors | 1 | 2004 | 1528 | 0.140 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2018 | 314 | 0.130 |
Why?
| | Biopsy | 1 | 2018 | 1056 | 0.120 |
Why?
| | Female | 12 | 2019 | 59913 | 0.120 |
Why?
| | Skin Neoplasms | 1 | 2002 | 761 | 0.120 |
Why?
| | Databases, Factual | 1 | 2019 | 1138 | 0.120 |
Why?
| | Trans-Activators | 1 | 2016 | 370 | 0.110 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2006 | 930 | 0.110 |
Why?
| | Adolescent | 6 | 2019 | 17889 | 0.110 |
Why?
| | Hypoproteinemia | 1 | 2012 | 4 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2335 | 0.100 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 19 | 0.100 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2013 | 178 | 0.100 |
Why?
| | Anemia, Iron-Deficiency | 1 | 2012 | 54 | 0.100 |
Why?
| | Edema | 1 | 2012 | 119 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 544 | 0.090 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 2009 | 7 | 0.090 |
Why?
| | DNA-Binding Proteins | 2 | 2008 | 1316 | 0.080 |
Why?
| | Anterior Chamber | 1 | 2009 | 20 | 0.080 |
Why?
| | Shock, Hemorrhagic | 1 | 2011 | 193 | 0.080 |
Why?
| | Apoptosis | 2 | 2010 | 2377 | 0.080 |
Why?
| | Astrocytoma | 1 | 2010 | 109 | 0.080 |
Why?
| | Treatment Outcome | 2 | 2018 | 9159 | 0.080 |
Why?
| | Colorado | 1 | 2018 | 4113 | 0.080 |
Why?
| | Blood Platelets | 1 | 2011 | 350 | 0.080 |
Why?
| | Eye Diseases | 1 | 2009 | 76 | 0.080 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2009 | 66 | 0.080 |
Why?
| | Acute Lung Injury | 1 | 2011 | 300 | 0.080 |
Why?
| | c-Mer Tyrosine Kinase | 4 | 2010 | 43 | 0.080 |
Why?
| | Reed-Sternberg Cells | 1 | 2007 | 2 | 0.070 |
Why?
| | Adenoids | 1 | 2007 | 10 | 0.070 |
Why?
| | Palatine Tonsil | 1 | 2007 | 32 | 0.070 |
Why?
| | Bone Marrow Transplantation | 1 | 2008 | 239 | 0.070 |
Why?
| | Drug Delivery Systems | 1 | 2009 | 301 | 0.070 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 13 | 0.070 |
Why?
| | Platelet Aggregation | 1 | 2006 | 94 | 0.070 |
Why?
| | Organ Transplantation | 1 | 2008 | 161 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 638 | 0.070 |
Why?
| | Adult | 6 | 2019 | 30718 | 0.060 |
Why?
| | Precancerous Conditions | 1 | 2007 | 156 | 0.060 |
Why?
| | Immunocompromised Host | 1 | 2007 | 197 | 0.060 |
Why?
| | Phagocytosis | 1 | 2006 | 355 | 0.060 |
Why?
| | Biliary Atresia | 1 | 2007 | 185 | 0.060 |
Why?
| | Wounds and Injuries | 1 | 2011 | 725 | 0.060 |
Why?
| | Lymph Nodes | 1 | 2007 | 423 | 0.060 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2009 | 863 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2007 | 1000 | 0.060 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2004 | 63 | 0.060 |
Why?
| | RNA, Viral | 1 | 2007 | 565 | 0.060 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2003 | 14 | 0.060 |
Why?
| | Immunoenzyme Techniques | 1 | 2003 | 193 | 0.050 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2004 | 96 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 1 | 2003 | 182 | 0.050 |
Why?
| | Brain Neoplasms | 1 | 2010 | 980 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2003 | 526 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2003 | 1127 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 1650 | 0.040 |
Why?
| | Macrophages | 1 | 2006 | 1284 | 0.040 |
Why?
| | Gene Knockdown Techniques | 2 | 2010 | 302 | 0.040 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 63 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2010 | 850 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2002 | 1805 | 0.040 |
Why?
| | Organic Cation Transporter 2 | 1 | 2016 | 8 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2004 | 2800 | 0.030 |
Why?
| | Disease Progression | 1 | 2002 | 2418 | 0.030 |
Why?
| | Cell Lineage | 1 | 2016 | 310 | 0.030 |
Why?
| | Risk Assessment | 1 | 2002 | 2987 | 0.030 |
Why?
| | Protein-Losing Enteropathies | 1 | 2012 | 11 | 0.030 |
Why?
| | Hypoalbuminemia | 1 | 2012 | 26 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1718 | 0.020 |
Why?
| | Platelet Activation | 1 | 2011 | 68 | 0.020 |
Why?
| | Middle Aged | 2 | 2019 | 26999 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 4440 | 0.020 |
Why?
| | Suppuration | 1 | 2009 | 7 | 0.020 |
Why?
| | Drug Evaluation, Preclinical | 1 | 2010 | 166 | 0.020 |
Why?
| | Injections, Spinal | 1 | 2009 | 102 | 0.020 |
Why?
| | Gene Expression Regulation, Leukemic | 1 | 2009 | 49 | 0.020 |
Why?
| | Cytarabine | 1 | 2009 | 52 | 0.020 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2009 | 83 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-6 | 1 | 2008 | 6 | 0.020 |
Why?
| | Mice, SCID | 1 | 2009 | 321 | 0.020 |
Why?
| | Inflammation | 1 | 2019 | 2499 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5077 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2009 | 560 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2009 | 704 | 0.020 |
Why?
| | Metalloproteases | 1 | 2006 | 37 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2011 | 2262 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1024 | 0.020 |
Why?
| | Solubility | 1 | 2006 | 226 | 0.020 |
Why?
| | Jurkat Cells | 1 | 2006 | 128 | 0.020 |
Why?
| | RNA, Neoplasm | 1 | 2006 | 80 | 0.020 |
Why?
| | Thromboembolism | 1 | 2006 | 93 | 0.020 |
Why?
| | Macrophage Activation | 1 | 2006 | 165 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2006 | 350 | 0.020 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 790 | 0.010 |
Why?
| | Animals | 3 | 2011 | 32102 | 0.010 |
Why?
| | Aged | 1 | 2002 | 19251 | 0.010 |
Why?
| | Young Adult | 1 | 2019 | 10470 | 0.010 |
Why?
| | Rats | 1 | 2011 | 5034 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2194 | 0.010 |
Why?
| | Mice | 2 | 2009 | 15052 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2006 | 1147 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1310 | 0.010 |
Why?
| | Cohort Studies | 1 | 2008 | 4944 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2009 | 1893 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2006 | 1756 | 0.010 |
Why?
|
|
Liang's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|